Silverback Therapeutics (NASDAQ:SBTX) Shares Down 4.6% – What’s Next?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) traded down 4.6% during mid-day trading on Thursday . The stock traded as low as $10.00 and last traded at $10.06. 1,367,808 shares were traded during trading, an increase of 305% from the average session volume of 337,931 shares. The stock had previously closed at $10.54.

Silverback Therapeutics Trading Down 4.6%

The stock has a market cap of $362.74 million, a P/E ratio of -4.16 and a beta of 0.60. The firm’s fifty day moving average is $10.46 and its 200 day moving average is $11.62.

About Silverback Therapeutics

Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.